PCYN (Procyon) ROE % Adjusted to Book Value: 7.79% (As of Jun. 2024)


PCYN Procyon Corp PCYN
48 GF Score
Price $0.20
View Full Analysis

What is Procyon ROE % Adjusted to Book Value?

Procyon PCYN 48 ROE % Adjusted to Book Value is 7.79% as of Jun. 2024. GuruFocus rates PCYN with a GF Score™ of 48/100.

Procyon's ROE % for the quarter that ended in Jun. 2024 was 6.70%. Procyon's PB Ratio for the quarter that ended in Jun. 2024 was 0.86. Procyon's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 was 7.79%.

Procyon ROE % Adjusted to Book Value Related Terms

Procyon ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Procyon's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Procyon ROE % Adjusted to Book Value Chart

Procyon Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.64 25.03 -5.05 -2.33 -16.16

Procyon Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.32 -5.67 -63.11 -23.57 7.79

PCYN vs KAYS, YCBD, CBDY: ROE % Adjusted to Book Value Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Procyon's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Procyon ROE % Adjusted to Book Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Procyon's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Procyon's ROE % Adjusted to Book Value falls into.


PCYN
48GF Score
Procyon Corp PCYN
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Procyon ROE % Adjusted to Book Value Calculation

Procyon's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-13.90% / 0.86
=-16.16%

Procyon's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=6.70% / 0.86
=7.79%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 7.79% mean?
Procyon (PCYN) has a ROE % Adjusted to Book Value of 7.79% as of Jun. 2024. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Procyon and its competitors.
Is Procyon's ROE % Adjusted to Book Value too high?
Procyon's current ROE % Adjusted to Book Value is 7.79%. Overall, Procyon has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Procyon's ROE % Adjusted to Book Value compare to KAYS and YCBD?
Procyon's ROE % Adjusted to Book Value of 7.79% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Procyon and its competitors. Procyon's current ROE % Adjusted to Book Value is 7.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Procyon stock overvalued right now?
Procyon (PCYN) has a current ROE % Adjusted to Book Value of 7.79%. The current ROE % Adjusted to Book Value is 7.79%. Procyon's overall GF Score™ is 48/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Procyon (PCYN), the current ROE % Adjusted to Book Value is 7.79% as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Procyon Business Description

Address 164 Douglas Road East, Oldsmar, FL, USA, 34677
Procyon Corp is a United-based company, through its subsidiary, it is engaged in developing and marketing proprietary medical products used to treat pressure ulcers, stasis ulcers, wounds, dermatitis, inflammation, and other skin problems. Its wound care products are sold through distributors to institutional customers such as hospitals, wound care clinics, skilled nursing facilities, home health agencies, and physicians and other healthcare practitioners. The firm's product lines are AMERX, AMERIGEL, and HELIX3 Bioactive Collagen. The skin and wound care products are marketed under the trademark AMERIGEL which contains the proprietary ingredient OAKIN which promotes wound healing and healthy skin. The corporation markets its products in the United States.
48GF Score

Get the complete analysis for PCYN

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.20
Price